Health

News Hour: Novartis has won U.S. approval for a copy of Amgen’s blockbuster arthritis drug Enbrel, but the Swiss drugmaker’s bid to muscle in on the medicine’s $4.7 billion (3.57 billion pounds) in annual U.S. revenue...

News Hour: Express Scripts Holding, the largest U.S. pharmacy benefit manager, said on Wednesday it will implement a program next year that guarantees per-patient spending caps on diabetes drug costs in an effort to limit soaring...

News Hour: The right mood music can influence how well people work together, a new management-oriented study suggests. Many retail establishments carefully select the music they play in order to influence consumer behavior, such as encouraging...

News Hour: Florida health officials on Tuesday said they were investigating three new Zika virus cases likely stemming from local mosquito bites in Miami-Dade County, including two cases outside of the known areas of active transmission....

News Hour: The U.S. Food and Drug Administration on Tuesday approved Novartis AG’s biosimilar version of Amgen Inc’s arthritis drug Enbrel. The FDA approved the drug, Erelzi, known also as etanercept-szzs, for multiple inflammatory conditions including...

News Hour: University of Michigan researchers on Tuesday said their own experiments undermine recent allegations of security flaws in St. Jude Medical Inc’s pacemakers and other implantable medical devices. Shares of St. Jude fell 5 percent...

News Hour: Sandoz, a Novartis division and the global leader in biosimilars, announced  that the US Food and Drug Administration (FDA) approved Erelzi (etanercept-szzs) for all indications included in the reference product label, including rheumatoid arthritis...

News Hour: For the first time, national data on 30-day mortality for patients with breast and lung cancer treated with chemotherapy have been collected and analysed in order to help clinical teams review and improve patient...

News Hour: Sanofi and Regeneron Pharmaceuticals, Inc.  announced detailed positive results from ODYSSEY ESCAPE, a Phase 3 trial which evaluated Praluent® (alirocumab) Injection in patients with an inherited form of high cholesterol known as heterozygous familial...

News Hour: The Novartis International Biotechnology Leadership Camp is a 3-day biotechnology seminar for top graduate and postgraduate students interested in pursuing a career in biotechnology. Novartis  opened the 13th International Biotechnology Leadership Camp (BioCamp). Over...